In a recently published clinical study, researchers found that once-weekly treatment with exenatide significantly reduced the levels of AD-related inflammatory proteins in patients with AD, such as soluble vascular cell adhesion protein 1 (sVCAM-1) and plasminogen activator inhibitor 1 (PAI-1) [136]. The gene discussed is VCAM1; the disease is Alzheimer disease.